Phlow Partners With USP On Continuous Manufacturing
Alliance To Validate Production Processes Could Be ‘Catalyst For Industry Change’
Executive Summary
Phlow Corp has announced a strategic alliance with the US Pharmacopeia to certify and validate continuous manufacturing processes as it aims to bolster US supplies of essential medicines. The company believes the move could serve as a catalyst for wider generics industry adoption of continuous manufacturing.
You may also be interested in...
US Plows $354m Into Phlow
US start-up Phlow has been awarded federal government funding of $354m as part of a contract to manufacture essential medicines in the US amid the COVID-19 pandemic, in partnership with AMPAC Fine Chemicals and Civica Rx.
Aspen Expects Growth Following Sandoz And Viatris Deals
Aspen expects to report significant growth in its continuing operations for the first half of its financial year, following deals with Sandoz and Viatris that have seen the South African firm divest major businesses in Japan and Europe.
Three Pillars Must Support Value Added Medicines In EU
Medicines for Europe has called for fresh efforts to bolster the value added medicines sector and “level the playing field” with the US and its 505(b)(2) pathway, launching a new report setting out the three key areas in which greater EU action is needed.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: